Pharmacological differences between beta-blockers and postoperative mortality following colon cancer surgery
Abstract β-blocker therapy has been positively associated with improved survival in patients undergoing oncologic colorectal resection. This study investigates if the type of β-blocker used affects 90-day postoperative mortality following colon cancer surgery. The study was designed as a nationwide...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-03-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-08736-6 |
| _version_ | 1819025872219275264 |
|---|---|
| author | Lovisa Ekestubbe Gary Alan Bass Maximilian Peter Forssten Gabriel Sjölin Yang Cao Peter Matthiessen Rebecka Ahl Hulme Shahin Mohseni |
| author_facet | Lovisa Ekestubbe Gary Alan Bass Maximilian Peter Forssten Gabriel Sjölin Yang Cao Peter Matthiessen Rebecka Ahl Hulme Shahin Mohseni |
| author_sort | Lovisa Ekestubbe |
| collection | DOAJ |
| description | Abstract β-blocker therapy has been positively associated with improved survival in patients undergoing oncologic colorectal resection. This study investigates if the type of β-blocker used affects 90-day postoperative mortality following colon cancer surgery. The study was designed as a nationwide retrospective cohort study including all adult (≥ 18 years old) patients with ongoing β-blocker therapy who underwent elective and emergency colon cancer surgery in Sweden between January 1, 2007 and December 31, 2017. Patients were divided into four cohorts: metoprolol, atenolol, bisoprolol, and other beta-blockers. The primary outcome of interest was 90-day postoperative mortality. A Poisson regression model with robust standard errors was used, while adjusting for all clinically relevant variables, to determine the association between different β-blockers and 90-day postoperative mortality. A total of 9254 patients were included in the study. There was no clinically significant difference in crude 90-day postoperative mortality rate [n (%)] when comparing the four beta-blocker cohorts metoprolol, atenolol, bisoprolol and other beta-blockers. [97 (1.8%) vs. 28 (2.0%) vs. 29 (1.7%) vs. 11 (1.2%), p = 0.670]. This remained unchanged when adjusting for relevant covariates in the Poisson regression model. Compared to metoprolol, there was no statistically significant decrease in the risk of 90-day postoperative mortality with atenolol [adj. IRR (95% CI): 1.45 (0.89–2.37), p = 0.132], bisoprolol [adj. IRR (95% CI): 1.45 (0.89–2.37), p = 0.132], or other beta-blockers [adj. IRR (95% CI): 0.92 (0.46–1.85), p = 0.825]. In patients undergoing colon cancer surgery, the risk of 90-day postoperative mortality does not differ between the investigated types of β-adrenergic blocking agents. |
| first_indexed | 2024-12-21T05:17:35Z |
| format | Article |
| id | doaj.art-bc959b43507d4ce2bdb7ee8a48ebc38d |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-21T05:17:35Z |
| publishDate | 2022-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-bc959b43507d4ce2bdb7ee8a48ebc38d2022-12-21T19:14:53ZengNature PortfolioScientific Reports2045-23222022-03-011211810.1038/s41598-022-08736-6Pharmacological differences between beta-blockers and postoperative mortality following colon cancer surgeryLovisa Ekestubbe0Gary Alan Bass1Maximilian Peter Forssten2Gabriel Sjölin3Yang Cao4Peter Matthiessen5Rebecka Ahl Hulme6Shahin Mohseni7School of Medical Sciences, Orebro UniversitySchool of Medical Sciences, Orebro UniversitySchool of Medical Sciences, Orebro UniversitySchool of Medical Sciences, Orebro UniversityClinical Epidemiology and Biostatistics, School of Medical Sciences, Orebro UniversitySchool of Medical Sciences, Orebro UniversitySchool of Medical Sciences, Orebro UniversitySchool of Medical Sciences, Orebro UniversityAbstract β-blocker therapy has been positively associated with improved survival in patients undergoing oncologic colorectal resection. This study investigates if the type of β-blocker used affects 90-day postoperative mortality following colon cancer surgery. The study was designed as a nationwide retrospective cohort study including all adult (≥ 18 years old) patients with ongoing β-blocker therapy who underwent elective and emergency colon cancer surgery in Sweden between January 1, 2007 and December 31, 2017. Patients were divided into four cohorts: metoprolol, atenolol, bisoprolol, and other beta-blockers. The primary outcome of interest was 90-day postoperative mortality. A Poisson regression model with robust standard errors was used, while adjusting for all clinically relevant variables, to determine the association between different β-blockers and 90-day postoperative mortality. A total of 9254 patients were included in the study. There was no clinically significant difference in crude 90-day postoperative mortality rate [n (%)] when comparing the four beta-blocker cohorts metoprolol, atenolol, bisoprolol and other beta-blockers. [97 (1.8%) vs. 28 (2.0%) vs. 29 (1.7%) vs. 11 (1.2%), p = 0.670]. This remained unchanged when adjusting for relevant covariates in the Poisson regression model. Compared to metoprolol, there was no statistically significant decrease in the risk of 90-day postoperative mortality with atenolol [adj. IRR (95% CI): 1.45 (0.89–2.37), p = 0.132], bisoprolol [adj. IRR (95% CI): 1.45 (0.89–2.37), p = 0.132], or other beta-blockers [adj. IRR (95% CI): 0.92 (0.46–1.85), p = 0.825]. In patients undergoing colon cancer surgery, the risk of 90-day postoperative mortality does not differ between the investigated types of β-adrenergic blocking agents.https://doi.org/10.1038/s41598-022-08736-6 |
| spellingShingle | Lovisa Ekestubbe Gary Alan Bass Maximilian Peter Forssten Gabriel Sjölin Yang Cao Peter Matthiessen Rebecka Ahl Hulme Shahin Mohseni Pharmacological differences between beta-blockers and postoperative mortality following colon cancer surgery Scientific Reports |
| title | Pharmacological differences between beta-blockers and postoperative mortality following colon cancer surgery |
| title_full | Pharmacological differences between beta-blockers and postoperative mortality following colon cancer surgery |
| title_fullStr | Pharmacological differences between beta-blockers and postoperative mortality following colon cancer surgery |
| title_full_unstemmed | Pharmacological differences between beta-blockers and postoperative mortality following colon cancer surgery |
| title_short | Pharmacological differences between beta-blockers and postoperative mortality following colon cancer surgery |
| title_sort | pharmacological differences between beta blockers and postoperative mortality following colon cancer surgery |
| url | https://doi.org/10.1038/s41598-022-08736-6 |
| work_keys_str_mv | AT lovisaekestubbe pharmacologicaldifferencesbetweenbetablockersandpostoperativemortalityfollowingcoloncancersurgery AT garyalanbass pharmacologicaldifferencesbetweenbetablockersandpostoperativemortalityfollowingcoloncancersurgery AT maximilianpeterforssten pharmacologicaldifferencesbetweenbetablockersandpostoperativemortalityfollowingcoloncancersurgery AT gabrielsjolin pharmacologicaldifferencesbetweenbetablockersandpostoperativemortalityfollowingcoloncancersurgery AT yangcao pharmacologicaldifferencesbetweenbetablockersandpostoperativemortalityfollowingcoloncancersurgery AT petermatthiessen pharmacologicaldifferencesbetweenbetablockersandpostoperativemortalityfollowingcoloncancersurgery AT rebeckaahlhulme pharmacologicaldifferencesbetweenbetablockersandpostoperativemortalityfollowingcoloncancersurgery AT shahinmohseni pharmacologicaldifferencesbetweenbetablockersandpostoperativemortalityfollowingcoloncancersurgery |